Curia Expands Glasgow Facility to Boost Sterile Fill-Finish Capabilities

• Curia Global, Inc. is expanding its sterile fill-finish facility in Glasgow, UK, adding an isolator-based vial filling line and lyophilizer to double GMP batch size.

• The company is also advancing its $200 million expansion in Albuquerque, NM, which includes two new filling lines and increased phase III clinical and commercial capacity.

Curia Global, Inc. has announced expansion plans for its sterile fill-finish facility in Glasgow, UK, alongside progress updates on its ongoing Albuquerque, NM expansion. The Glasgow site will introduce an integrated isolator-based vial filling line and lyophilizer, significantly increasing its GMP batch size and enhancing capabilities for highly potent drug products.

The Glasgow expansion will more than double the current batch size, enabling up to 20,000 vials per run. The facility, known for its expertise in antibody-drug conjugates (ADCs), lipid nanoparticles (LNPs), lyophilization development, and complex formulations, will further strengthen its sterile injectable drug product development services from pre-formulation to commercial manufacturing. The addition of robotic, lossless filling technology within an isolator will also allow filling speeds five times faster than the site’s current capacity. The new lyophilizer will support clinical-stage clients with increased scalability and small-volume commercial fills.

“Our investment in Glasgow underscores Curia’s commitment to being an end-to-end partner,” said Philip Macnabb, CEO of Curia. “So much innovation exists in the early stages of clinical development, and Curia is eager to meet the growing demand for increased capacity for our clinical-stage clients.”

Curia is also progressing with its $200 million multi-year expansion project in Albuquerque. The site will gain two isolated filling lines, adding over 70,000 square feet to its manufacturing space. The VarioSysTM Flex Line, designed for small-scale biologics and non-potent small molecules, is currently in commissioning, while a new high-speed vial line with autoloaded freeze dryers and automated vial inspection is set to begin commissioning in Q3 2025.

With these expansions, Curia continues to strengthen its global sterile fill-finish network, which includes additional facilities in Camarillo and Thousand Oaks, CA, and Burlington, MA. The company’s investments aim to address growing demand for biologics, GLP-1 agonists, and contract manufacturing capacity.